Share Name Share Symbol Market Type Share ISIN Share Description
Feedback Plc LSE:FDBK London Ordinary Share GB0003340550 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 1.725p 1.70p 1.75p 1.725p 1.725p 1.725p 43,252 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Electronic & Electrical Equipment 0.5 -0.3 -0.1 - 4.25

Feedback Share Discussion Threads

Showing 1751 to 1774 of 1775 messages
Chat Pages: 71  70  69  68  67  66  65  64  63  62  61  60  Older
DateSubjectAuthorDiscuss
16/2/2018
12:18
Tipped by Shareprophets yesterday.
philjeans
14/2/2018
20:14
New CEO , Ultra Positive New TexRAD study ,, NNS soon with more good news - Of a total of 152 lung cancer patients analysed for heterogeneity, 124 (82%) were discussed at the MDT meeting. The TexRAD results were used for research purposes only and were not used to alter any individual patient’s treatment. The study suggests that there is a huge potential for the implementation of quantitative imaging in the assessment of tumour heterogeneity and engagement from radiologists is key to its success. hxxps://t.co/dQdscuflIu
botack
14/2/2018
19:17
New Director will be BUYING/HAS BOUGHT; and we await more contract news. RNS made it very clear they are determined to forge ahead. Added today.
philjeans
14/2/2018
18:30
I'm sure you are right about TB. He will sell into any strength. He should be gone before end of year.
lr2
14/2/2018
17:27
Good appointment and looks like Mr.Brown has dropped another 1m plus
ducatiman
12/2/2018
19:59
Could be Phil, our ex director seller must have a limit price to sell. Once he is out of the way!
ducatiman
12/2/2018
18:37
Picked up a few more here today - seems a very good time to BUY.
philjeans
09/2/2018
12:34
Mr.Cranston taking up the slack!
ducatiman
06/2/2018
14:17
Makes sense. He would only sell into any good news release.
lr2
06/2/2018
14:13
They are waiting until he is out!
ducatiman
05/2/2018
18:29
End November at the current rate of offloading. At least he suffers like the rest of us. Every time he sells the price drops making his remaining holding worth even less. We need a good news release to disperse the gloom. Here's hoping it will turn up soon.
lr2
05/2/2018
18:20
So he's down to 10%, not too long and he should be out.
ducatiman
03/1/2018
20:25
desflurane TexRAD is not for early stage cancer , It has no current valid competitors in its unique field , PLease refer to the long drawn out explanation by Balaji Ganeshan above ,, Happy Reading
botack
03/1/2018
18:28
Is this more competition for TexRAD? The article states further down:- "A separate AI programme has been developed to pick up early signs of lung cancer" http://www.dailymail.co.uk/sciencetech/article-5231555/AI-doctor-automatically-diagnose-heart-disease.html?ito=email_share_article-top
desflurane
03/1/2018
17:52
BOTACK, thank you.
ducatiman
03/1/2018
17:43
Botack,good work and many thanks for your efforts.
ashtree2
03/1/2018
13:10
GLA , ill gladly answer any questions. NB I have 16 years experience in the field one of those announcements add up to much. They were 2015 and in the case of the OeMS the software from TexRad was bundled in with the scanner. The scanners cost $2m and the TexRad software was probably at cost as a research collaboration -£50k? In the case of Siemens it was facilitated by the Korean distributor of Siemens radioisotopes , and as such not directly linked to Siemens Healthcare - the scanner side of the company.” The first sale in 2015 in South-Korea where the TexRAD software was part of the scanner purchase tender which eventually went to Siemens and was facilitated with their distributor. Moving forward South-Korea is turning out to be a very important emerging market for TexRAD with a very able and well-connected distributir. Similarly in China there is a distributor for TexRAD who is a one of the exclusive approved vendors for GE to tap the huge Chinese market. View Balaji’s profile Balaji Ganeshan Re the specific point on the GE/Siemens product which is more in detection of nodules not what TexRAD does. Siemens GE products are in detection whereas TexRAD is for risk-stratification at the time of staging after the cancer is detected - That’s why big-companies are talking to us to fill the gap - they have tools for detection and TexRAD provides risk-stratification information for example on staging PET/CT in lung cancer after the cancer is detected - TexRAD is required for personalised medicine/treatment
botack
03/1/2018
13:09
“They are huge tumours that any decent radiologists would call as cancerous.” This is exactly where TexRAD can make a huge difference - there maybe tumours of similar size/stage but have totally different outcomes which the TexRAD texture heterogeneity could add another dimension and provide information on the missing link and potentially pick up aggressive tumour phenotype for whom a personalised treatment approach will be most desired. There has been numerous evidence demonstrating the same using TexRAD in prognosis (TexRAD could identify which patients will have good prognosis which will have poor prognosis independent current good-standards e.g. clinical stage etc.) and treatment-response/prediction (identify early which patients will benefit from targeted/novel therapies and who will not...) - these applications will essentially bring about improved patient outcomes in a cost-effective manner!
botack
03/1/2018
13:08
“I'm not invested ( as you probably could guess) but will watch to see how far this goes. NB there are about 70 PETCT scanners in the UK and probably 800 in Europe although several thousands CT scanners.” Demonstrates the huge-market in the UK, Europe and beyond... View Balaji’s profile Balaji Ganeshan “None of the images in the presentations I have seen are small lesions (the most important to detect).” Yes that is also another important area in early detection of cancer something that could be the focus in the near future. There is however quite a few commercial systems in the market for this application as a “second-read” which although been in the market for number of years has still not been well-received and been a commercial success as there are issues with clinical-confidence and accuracy in such systems which on the contrary has potential to increase clinical work-load. Also the extensive-work and evidence required for regulatory-approvals is quite prohibitory. View Balaji’s profile Balaji Ganeshan “Nor are they equivocal and later after Texture analysis turn out to be cancerous.” Disease-severity assessment few examples in renal lesions, liver lesions, prostate cancer demonstrates the application of TexRAD on routinely acquired CT and MRI adding value in identifying which equivocal lesion is actually significant cancer which is non-significant cancer for example in prostate and enhancing radiological practice and confidence in decision making (demonstrated improved accuracy for differentiating between lesion sub-types in liver and kidney lesions
botack
03/1/2018
13:06
“I'm sure there is money to be made on a spike with such a small mcap BUT as someone with skin in the game of advanced CT and PETCT visualisation .....buyer beware! Also Alliance Medical just want to make a profit on the scans...they dont want to add complicated addons to their own PACS. Radiologists dont want to use software that adds to reporting time - they are time pressed enough as it is.” Alliance Medical being one of the major private diagnostic imaging service provider in the UK (few other European-countries) where majority of diagnostic imaging data (PET/CT, MRI etc.) goes through their network. Alliance are keen to incorporate TexRAD analysis within their radiology/nuclear-Medicine workflow to provide added-value to their diagnostic service to the various NHS hospital trusts. It is true that Alliance and their reporting physicians (Radiologists/Nuclear-Medicine physicians) don’t want to add complicated add-ons nor increase the reporting time and for this reason the recently CE marked TexRAD Lung is an automated/hands-free solution which post-processes the PET/CT images in lung cancer patients in the background and results are ready / incorporated within the PACS for the individual patients in-advance to seamlessly fit within the radiologists/Nuclear-Medicine physicians reporting workflow. So the latest-development are such which is/will be well received by all the stakeholders - end-users/Hospital-IT etc and a subscription model will result in revenue generation.
botack
03/1/2018
13:05
“GE Healthcare and Siemens plus Toshiba and Philips make all of the PETCT scanners and most of the CT and MRI. For instance in CT software analysis: GE have LUNGVCAR and Siemens have LUNGCare. GE also have PETVCAR, ThoracicVCAR and COLONVCAR.cs GLA and DYOR on the competition.....PS: GE and Siemens usually bundle the software into a sales package when they sell a scanner to a hospital. Buy the scanner.... get the software cheap or free etc.” True in terms of how the big guys provide their offerings (bundling the software within scanner purchase where the scanners are big-prices item / capital purchase compared to the softwares) but at the same time in the current intense competition between the OEMs to win the orders for scanners, innovative softwares like TexRAD is providing as a differentiator to the scanner purchase/tender decision making etc - this is what in fact TexRAD has found where the big guys have reached out to TexRAD to partner with them in different geographies not just as a distributor/partner but potentially as technological partner for integration. Secondly the current/major focus in medical imaging technology and advancement is how best to harness and quantify data (big-data analysis, visualisation, quantification & AI/machine-learning) from the very exquisite images coming from the scanners (there is now very little/incremental benefit from any future advancement in hardware scanner technologies expected in the near-future). This is where the TexRAD software visualisation and quantification and data-mining/Machine-learning comes into the picture filling the gap in the Medical imaging industry.
botack
03/1/2018
13:04
From Balaji Ganeshan - Hope the following help,s to clarify “I dont know whether Feedback is a one trick pony - TexRad but TexRad has a lot of competition.” TexRAD no doubt is the flagship product although within Feedback and its subsidiaries there is lot of experience in other medical imaging software analysis (e.g. perfusion / blood flow assessment on dynamic contrast enhanced - DCE-CT) and new products waiting to be released in the near future. —- TexRAD having “Lot of competition” not sure what is referred by this? A lot of commercially available texture analysis software (direct-competitors)? If so there are not “lot” in the market - no doubt there is lot of interest in texture analysis and Radiomics (extraction of metrics from radiological-scans such as CT, MR etc...) with few research institutions and companies dabbling in this space - which demonstrates great potential in this area. If no competition then there is no market no appetite - so competition is not bad in fact in a way assists in marketing TexRAD which everyone knows and recognises as TexRAD has been a pioneer in this space. However none of the apparent competitors if any have the brand-name and validation/recognition and market penetration/lead around the world. TexRAD has tonnes of peer reviewed journal and conference presentations (100+ - just in the recently concluded Premier Radiology conference RSNA 2017 there were around 20+ presentations only on TexRAD from the illustrious customers of TexRAD from around the world). There are around - 50 and growing prolific hospitals around the world who are TexRAD customers forming a strong advocate and TexRAD community. TexRAD has pioneered this niche area of development in medical imaging and has a massive lead over small and big companies/OEMs owing to the large amount of evidence based research accumulated over the years which is no mean feat to emulate for any company - big or small.
botack
03/1/2018
07:22
Good Morning to All Recently we have had some posts on here and LSE bb,s from a poster claiming to be an industry expert who has taken it upon themselves to claim TexRAD is nothing more than another piece of worthless Medical Imaging tech that's only good for sending his esteemed colleagues asleep , All discussion on the future of Feedback plc is welcome from any quarter especially so from an industry participating " expert " radiologist, That person did raise some valid points but its not really cricket to be disrespectful of a technology or that technologies designer / creator without knowing what that tech can do, which quite clearly CroasdaleIfc does not but choose to be derogatory anyway for blatantly ulterior motives that is up to the individual to interpret Dr Balaji Ganeshan has been kind enough to spend time and make a lot of effort to answer Croasdalelfc claims SO Should he give permission , Its a long detailed reply to all the questions that """"" raised I will post his response , Like I stated on both bb,s I am not a Doctor,Physician or Scientist so not in a position to reply on the technicalities so will contact a person who is , Balaji has been kind enough and addressed the situation
botack
02/1/2018
17:08
Off the bottom!
ducatiman
Chat Pages: 71  70  69  68  67  66  65  64  63  62  61  60  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20180219 11:25:54